Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report
oleh: Shetal A. Patel, MD, PhD, Young Whang, MD, PhD, Chaely Medley, NP, Kevin Chen, PharmD, Jasmine Jordan, BS, Dante Bortone, PhD, Benjamin Vincent, MD, PhD, Jared Weiss, MD
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2024-10-01 |
Deskripsi
A 20-year-old man with metastatic large cell neuroendocrine carcinoma of the lung was treated with the delta-like ligand 3–targeting bispecific T cell engager, tarlatamab. Treatment was complicated by transient cytokine release syndrome but resulted in a partial response. Bispecific T cell engagers may offer a novel treatment approach for large cell neuroendocrine carcinoma of the lung.